Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
While network-based proximity predicts drug association based on the distance between drug targets and candidate genes, FUMA provides the gene table mapped to the drug database based on the prioritized genes by different mapping methods such as position, eQTL, and chromatin interaction.Network-based in silico drug repurposing on PSCDrugBank idDrug NameDescriptionIndicationzpDB00004Denileukin diftitoxCD25-directed cytotoxinCutaneous T-cell lymphoma−5.4432.63 × 10−8DB05299Keyhole limpet hemocyanin*Immune modulatorBladder cancer, solid tumors−4.0202.91 × 10−5DB06584TG4010*Cancer vaccine expressing MUC1/IL2Breast cancer, renal cell carcinoma, prostate cancer, non-small cell lung cancer.−3.5611.85 × 10−4DB05304Girentuximab*Chimeric monoclonal antibody targeting carbonic anhydrase IXRenal cell carcinoma−3.5262.11 × 10−4DB06083Tapinarof*Aryl hydrocarbon receptor-modulating agentPlaque psoriasis−3.0131.29 × 10−3DB04901Galiximab*Anti-CD80 monoclonal antibodyNon-Hodgkin’s lymphoma, psoriasis−2.7403.07 × 10−3DB00163Vitamin EVitaminDietary supplement−1.9180.0276DB06421Declopramide*DNA repair inhibitorsColorectal cancer, inflammatory bowel disease.−1.5930.0556DB06362Becatecarin*DNA intercalating agent, topoisomerase I and II inhibitorGastric cancer, adenocarcinoma of unknown origin, gall bladder or pancreatic tumors, breast cancer, renal cell cancer, colorectal cancer−1.5420.0615DB05022Amonafide*DNA intercalating agent, topoisomerase II inhibitorBreast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia−1.5420.0616DB08934SofosbuvirN55B RNA polymerase inhibitorChronic hepatitis C infection−1.3420.0898DB05127ANA971*Toll-like receptor 7Chronic hepatitis C infection−1.3380.0904DB04860Isatoribine*Toll-like receptor 7Chronic hepatitis C infection−1.3380.0904DB11094Vitamin DVitaminOsteoporosis prevention, Vitamin D insufficiency/deficiency, hypoparathyroidism, refractory rickets, familial hypophosphatemia−0.5150.3033DB01586Ursodeoxycholic acidGallstone dissolution agentGallstones, PBC0.1700.5673DrugBank id, DrugBank database identifier; Drug Name, drug name; Indication, current drug-treatment; z, relative proximity between PSC candidate genes and relevant drug of genes; p, P-value of the relative proximity. *Asterisk indicates not FDA-approved agent.
Source: Network-based proximity predicts drug-PSC associations for drug repurposing. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis
Study design awaiting verification · Nature Communications · 2023
Original publication title
Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Primary sclerosing cholangitis (PSC) is a rare autoimmune bile duct disease that is strongly associated with immune-mediated disorders. In this study, we implemented multitrait joint analyses to genome-wide association summary statistics of PSC and numerous clinical and epidemiological traits to estimate the genetic contribution of each trait and genetic correlations between traits and to identify new lead PSC risk-associated loci. We identified seven new loci that have not been previously reported and one new independent lead variant in the previously reported locus.
Functional annotation and fine-mapping nominated several potential susceptibility genes such as MANBA and IRF5. Network-based in silico drug efficacy screening provided candidate agents for further study of pharmacological effect in PSC.
The genetic basis of primary sclerosing cholangitis has only been partially uncovered. Here, the authors perform a multitrait genome-wide association study to provide insight into the genetic etiology of primary sclerosing cholangitis risk and possible therapeutic drug targets.
Authors’ abstract
Primary sclerosing cholangitis (PSC) is a rare autoimmune bile duct disease that is strongly associated with immune-mediated disorders. In this study, we implemented multitrait joint analyses to genome-wide association summary statistics of PSC and numerous clinical and epidemiological traits to estimate the genetic contribution of each trait and genetic correlations between traits and to identify new lead PSC risk-associated loci. We identified seven new loci that have not been previously reported and one new independent lead variant in the previously reported locus.
Functional annotation and fine-mapping nominated several potential susceptibility genes such as MANBA and IRF5. Network-based in silico drug efficacy screening provided candidate agents for further study of pharmacological effect in PSC.
The genetic basis of primary sclerosing cholangitis has only been partially uncovered. Here, the authors perform a multitrait genome-wide association study to provide insight into the genetic etiology of primary sclerosing cholangitis risk and possible therapeutic drug targets.
Publication and source details
Original title: Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis
Younghun Han; Jinyoung Byun; Catherine Zhu; Ryan Sun; Julia Y. Roh; Heather J. Cordell; Hyun-Sung Lee; Vikram R. Shaw; Sung Wook Kang; Javad Razjouyan; Matthew A. Cooley; Manal M. Hassan; Katherine A. Siminovitch; Trine Folseraas; David Ellinghaus; Annika Bergquist; Simon M. Rushbrook; Andre Franke; Tom H. Karlsen; Konstantinos N. Lazaridis; The International PSC Study GroupSchrammChristoph24ShapiroDavid25GoodeElizabeth26; Katherine A. McGlynn; Lewis R. Roberts; Christopher I. Amos
Nature Communications · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T20:22:07.108200+00:00
DOI: 10.1038/s41467-023-36678-8 · PMC9958016